Clinical contributions of exhaled volatile organic compounds in the diagnosis of lung cancer.
T. Oguma, T. Nagaoka, M. Kurahashi, N. Kobayashi, S. Yamamori, C. Tsuji, H. Takiguchi, K. Niimi, H. Tomomatsu, K. Tomomatsu, N. Hayama, T. Aoki, T. Urano, K. Magatani, S. Takeda, T. Abe, K. Asano
PLoS ONE 2017 ;12(4):e0174802. PubMed: 28384298
AbstractExhaled volatile organic compounds (VOC) are being considered as biomarkers for various lungs diseases, including cancer. However, the accurate measurement of extremely low concentrations of VOC in expired air is technically challenging. We evaluated the clinical contribution of exhaled VOC measured with a new, double cold-trap method in the diagnosis of lung cancer. Breath samples were collected from 116 patients with histologically confirmed lung cancer and 37 healthy volunteers (controls) after inspiration of purified air, synthesized through a cold-trap system. The exhaled VOC, trapped in the same system, were heat extracted. We analyzed 14 VOC with gas chromatography. The concentrations of exhaled cyclohexane and xylene were significantly higher in patients with lung cancer than in controls (p = 0.002 and 0.0001, respectively), increased significantly with the progression of the clinical stage of cancer (both p < 0.001), and decreased significantly after successful treatment of 6 patients with small cell lung cancer (p = 0.06 and 0.03, respectively). Measurements of exhaled VOCs by a double cold-trap method may help diagnose lung cancer and monitor its progression and regression.
with link to compound page
|Structure||Number of references|
|No associated compound.|